Adapted from the Product Monograph.

Patients were enrolled without requiring a minimum baseline blood eosinophil or other type 2 inflammatory biomarkers. A severe exacerbation was defined as a deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days, or hospitalization or ER visit due to asthma that required systemic corticosteroids.

Adapted from the Product Monograph.

Study population

In VENTURE, enrolled subjects were receiving high-dose inhaled corticosteroids plus additional controller(s). All subjects were receiving OCS. After optimizing OCS dose (screening period), subjects were randomized and continued to receive their existing asthma medicine during the study; however their OCS dose was reduced every 4 weeks during the OCS reduction phase (weeks 4-20), if asthma control was maintained. Asthma control was maintained if subjects did not experience i) an increase in ACQ-5 ≥0.5 units, ii) a severe asthma exacerbation, or iii) a clinically significant event that required OCS dose adjustment. Patients were enrolled without requiring a minimum baseline blood eosinophil or other type 2 inflammatory biomarkers.